|
Market Closed -
Saudi Arabian S.E.
16:39:59 22/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 121.40 SAR | -0.33% |
|
-3.88% | -14.69% |
| 10-23 | Jamjoom Pharma Partners with Mubadala Bio for Inflammation Drug Distribution in UAE | MT |
| 10-22 | Jamjoom Pharmaceuticals' Attributable Net Profit, Revenue Rise | MT |
Chart: Technical Analysis
Saudi Arabian S.E.SAR
| Markets | Quality | ||
|---|---|---|---|
Saudi Arabian S.E.
| 4015 | Delayed |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Bearish |
| Resistance | 129.5 | 137.2 | 136.8 |
| Spread/Res. | -6.25% | -11.52% | -11.26% |
| Spread/Supp. | +3.41% | +10.77% | +6.49% |
| Support | 117.4 | 109.6 | 114 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- 4015 Stock
- Charts Jamjoom Pharmaceuticals Factory Company
Select your edition
All financial news and data tailored to specific country editions
